| Ape Virus Shrinks Mesothelioma Tumors in Lab |
Posted on Friday, December 27, 2013.
Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells.
While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma xenografts. GALV carrying a “prodrug activator gene” (which triggers expression of a suicide gene in infected cells) efficiently killed ACC-MESO-1 mesothelioma cells.
The result was “significant inhibition” of mesothelioma tumor growth in the mice. Further testing showed that the ACC-MESO-1 mesothelioma cells had more cellular receptors for GALV than do normal mesothelial cells or even other types of mesothelioma cells, suggesting that GALV could effectively target these cancer cells and leave healthy cells alone.
In an article summarizing these findings in Cancer Gene Therapy, the Japanese research team concluded, “These data indicate the potential utility of GALV… in the treatment of mesothelioma.” The use of GALV or another viral vector, such an adenovirus (cold virus), to carry anti-cancer information into mesothelioma or other cancer cells is known as virotherapy or gene therapy. Research into this and other novel cancer treatments is especially important for mesothelioma, a fast-growing cancer which rarely responds to standard therapies.
Source:
Kubo, S, et al, “Highly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virus”, November 8, 2013, Cancer Gene Therapy, Epub ahead of print.
DISCLAIMER: : Surviving Mesothelioma® is registered with the United States Patent and Trademark Office by Cancer Monthly, Inc. and the website is owned and managed by Cancer Monthly Inc. All of the information provided on this website or by any employee or contractor of Cancer Monthly is for informational purposes only. This website is not a substitute for professional medical advice, examination, diagnosis or treatment. This website should not be used for diagnosing or treating a health problem or disease and it is not a substitute for professional care. You should always seek the advice of your physician or other qualified health professional before starting any new treatment or making any changes to an existing treatment. You should not delay in seeking or disregard medical advice based on information on this website or by any employee or contractor of Cancer Monthly.
0 comments:
Post a Comment